News
Agis KydonieusAgis Kydonieus is the founder and president of Samos Pharmaceuticals LLC and cofounder of KAT Transdermals LLC and InteguRx Therapeutics LLC. He has 30+ years of extensive experience in preclinical as well as phase I–III clinical development and has launched several products in the…
This issue of the CRS Newsletter contains a fascinating summary of five published articles that have some focus on animals as a source of compounds with the potential to treat human conditions or as models to facilitate understanding of disease and biological functions. Of particular interest are…
Introduction In non-small cell lung cancer (NSCLC), the level of oxygenation surrounding the cancerous cells is low compared with normal tissue owing to the rapid growth of the tumor cells. The decreased blood circulation results in development of pockets of lower oxygen levels, resulting in…
Macromolecular prodrugs (MP), or polymer–drug conjugates, are successful tools of drug delivery investigated broadly toward optimization of pharmacokinetics of drugs.1 Specific advantage is gained when, for example, the polymer increases solubility of the drug or aids in localizing an enhanced…
I jotted notes for this update as I flew back from the Partnership Opportunities for Drug Delivery (PODD) conference in Boston. CRS was well represented at this conference. The conference, now in its fourth year, was again chaired by Board of Scientific Advisors (BSA) member Barbara Lueckel.…
Introduction
Fibrin hydrogels are protein-based scaffolds frequently used in tissue engineering for delivery of bioactive payloads (e.g., growth factors). Conventional fibrin scaffolds enable very limited spatial and temporal control of payload release, especially after implantation. This is…
